AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...

AstraZeneca Pharma India reported its financial results for Q2 FY25, showing a notable revenue increase. Revenue from ...

RSV symptoms include cough, fever, running nose, irritability, reduced activity, and pauses in breathing. Severe cases can ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

AstraZeneca Pharma tumbled 5.12% to Rs 6,768 after the pharmaceutical firm's net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24.

The pneumococcal conjugate vaccine—known as PCV—prevents around 30 percent of pneumonia, the most common cause of childhood ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...